Cardiac involvement in genotype-positive Fabry disease patients assessed by cardiovascular MR
Abstract
Objective: Cardiac magnetic resonance (CMR) has the potential to provide early detection of cardiac involvement in Fabry disease. We aimed to gain further insight into this by assessing a cohort of Fabry patients using CMR. Methods/results: Fifty genotype-positive Fabry subjects (age 45±2 years; 50% male) referred for CMR and 39 matched controls (age 40±2 years; 59% male) were recruited. Patients had a mean Mainz severity score index of 15±2 (range 0–46), reflecting an overall mild degree of disease severity. Compared with controls, Fabry subjects had a 34% greater left ventricular mass (LVM) index (82±5 vs 61±2 g/m2, p=0.001) and had a significantly greater papillary muscle contribution to total LVM (13±1 vs 6±0.5%, p<0.001), even in the absence of left ventricular hypertrophy (LVH). Late gadolinium enhancement (LGE) was present in 15 Fabry subjects (9/21 males and 6/23 females). The most common site for LGE was the basal inferolateral wall (93%, 14/15). There was a positive association between LVM index and LGE. Despite this, there were two males and three females with no LVH that displayed LGE. Of Fabry subjects who were not on enzyme replacement therapy at enrolment (n=28), six were reclassified as having cardiac involvement (four LVH-negative/LGE-positive, one LVH-positive/LGE-positive and one LVH-positive/LGE-negative). Conclusions: CMR was able to detect cardiac involvement in 48% of this Fabry cohort, despite the overall mild disease phenotype of the cohort. Of those not on ERT, 21% were reclassified as having cardiac involvement allowing improved risk stratification and targeting of therapy.Keywords
This publication has 16 references indexed in Scilit:
- A disproportionate contribution of papillary muscles and trabeculations to total left ventricular mass makes choice of cardiovascular magnetic resonance analysis technique critical in Fabry diseaseJournal of Cardiovascular Magnetic Resonance, 2015
- Relation of Burden of Myocardial Fibrosis to Malignant Ventricular Arrhythmias and Outcomes in Fabry DiseaseThe American Journal of Cardiology, 2014
- Differences in Fabry Cardiomyopathy Between Female and Male PatientsJACC: Cardiovascular Imaging, 2011
- Cardiovascular Events in Patients With Fabry DiseaseJACC, 2011
- Prominent Papillary Muscles in Fabry Disease: A Diagnostic Marker?Ultrasound in Medicine & Biology, 2011
- Long-Term Effects of Enzyme Replacement Therapy on Fabry CardiomyopathyCirculation, 2009
- Fabry's diseaseThe Lancet, 2008
- The Mainz Severity Score Index (MSSI): development and validation of a system for scoring the signs and symptoms of Fabry diseaseActa Paediatrica, 2006
- OsiriX: An Open-Source Software for Navigating in Multidimensional DICOM ImagesJournal of Digital Imaging, 2004
- The Mainz Severity Score Index: a new instrument for quantifying the Anderson–Fabry disease phenotype, and the response of patients to enzyme replacement therapyClinical Genetics, 2004